Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the target of a large increase in short interest in January. As of January 30th, there was short interest totaling 61,344 shares, an increase of 213.1% from the January 15th total of 19,594 shares. Approximately 9.0% of the shares of the stock are sold short. Based on an average daily volume of 506,631 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily volume of 506,631 shares, the days-to-cover ratio is presently 0.1 days. Approximately 9.0% of the shares of the stock are sold short.

Biodexa Pharmaceuticals Stock Down 9.9%

Shares of BDRX opened at $1.09 on Friday. The stock’s 50-day moving average price is $2.86 and its two-hundred day moving average price is $5.14. Biodexa Pharmaceuticals has a 12 month low of $1.08 and a 12 month high of $50.90.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Wall Street Zen raised shares of Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.